[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637792":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":48,"collaborators":21,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":21,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":21,"enrollmentInfo":60,"targetDuration":21,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":34,"whyStopped":21,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Group (PULSAR + Immunotherapy)","EXPERIMENTAL","Patients with unresectable locally advanced gastric cancer who did not progress after 3 or more cycles of first-line immunotherapy-containing systemic therapy will receive personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR)",[13,14],"Radiation: PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy)","Radiation: PULSAR",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"RADIATION","PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy)","Dose Schedule: 6 Gy per fraction administered every 3-4 weeks",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"PULSAR","Administer a single dose of 6 Gy of radiation, up to a total of 3 cycles, at 3-4 week intervals, along with standard systemic therapy.",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":21,"email":31},"Jeong Il Yu","CONTACT","+82234109598","ro.yuji651@gmail.com",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":21,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Seoul","Select Province\u002FState","06351","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.9784,37.566,{"lat":43,"lon":42},[46],{"name":28,"role":29,"phone":47,"phoneExt":21,"email":31},"0234109598",{"type":49,"investigatorFullName":28,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Associate Professor","100637792","pulsar-combined-with-immunotherapy-for-unresectable-locally-advanced-gastric-cancer-100637792",false,"NCT07607119","PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer","A Prospective Phase II Study of Systemic Therapy With Immunotherapy Combined With Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Unresectable Locally Advanced Gastric Cancer","Inclusion Criteria:\n\nAge 19 or more years. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed gastric adenocarcinoma. Tumor biomarker status: HER-2 negative, EBV negative, and Microsatellite Stable (MSS).\n\nUnresectable, locally advanced extent at initial staging (Para-aortic lymph node \\[PALN\\] and Supraclavicular lymph node \\[SCN\\] metastases are allowed).\n\nHas completed 3 or more cycles of first-line systemic therapy combined with immunotherapy without evidence of disease progression.\n\nPresence of at least one evaluable lesion according to RECIST v1.1 that is deemed safely irradiable by the investigator.\n\nVoluntary written informed consent provided by the subject.\n\nExclusion Criteria:\n\nPregnant or lactating women. Presence of brain metastases or leptomeningeal involvement. Prior history of radiation therapy to the intended target site. Severe uncontrolled comorbidities that, in the investigator's opinion, limit study participation or treatment compliance (e.g., uncontrolled infection, heart failure, arrhythmia, psychiatric illness).\n\nInability or unwillingness to comply with the study protocol procedures. Any condition deemed inappropriate for study participation by the principal investigator or attending physician.","ALL","19 Years",{"count":61,"type":62},53,"ESTIMATED","INTERVENTIONAL",[65],"NA","The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.",[68,69,70,71],"Gastric Adenocarcinoma","Stomach Neoplasms","Locally Advanced Gastric Cancer","Unresectable Gastric Cancer",[73,74],"HER2-negative Stomach Cancer","Microsatellite Stable Gastric Cancer","2026-05-24",{"date":77,"type":78},"2026-05-28","ACTUAL",{"date":80,"type":78},"2026-05-15",{"date":82,"type":62},"2030-04-30",{"name":5,"class":6},1]